A Blood Test for CTE Is Finally on the Horizon — What Athletes Need to Know

For decades, the cruelest thing about CTE was the waiting. Players, families, and doctors could suspect it and argue about it. They could even watch the symptoms pile up. But nobody could actually confirm it while the person was still alive. The only definitive diagnosis came after death, under a microscope, from donated brain tissue.

That may be about to change. In November 2026, researchers at Boston University and Banner Health reported in the Journal of the American Medical Association (JAMA) that a simple blood test may be able to detect CTE during life. A second, independent team reached a similar conclusion in the very same issue. It’s early, it’s small, and it’s not something you can book at your local clinic yet. But for anyone who plays a contact sport, it is the most hopeful CTE news in years.

What CTE Actually Is — and Why It Stayed Invisible

CTE stands for chronic traumatic encephalopathy. It’s a degenerative brain disease linked to repeated head impacts. Football players, boxers, rugby players, and military veterans accumulate them over years. They come not just from diagnosed concussions but from the thousands of smaller hits that never make the injury report.

Inside the brain, a protein called tau misfolds and tangles up inside brain cells. Over time, those tangles damage memory, mood, behaviour, and thinking. The symptoms — depression, irritability, confusion, memory loss — often show up years after the playing days end. That delay is part of what makes the disease so hard to pin down. Is it CTE, or depression, or early Alzheimer’s, or just getting older? Without a way to see the disease in a living brain, doctors had to guess.

That guessing is the problem the new research attacks. If a blood test can spot the tau tangles of CTE while someone is alive, everything changes. Diagnosis, clinical trials, and treatment research would all change. The decisions athletes make about their careers would change too.

The New Study: 21 Players, One Blood Marker

Here’s what the Boston University team actually did. They studied 21 former American football players who had given blood during their lives and then donated their brains to the BU CTE Center Brain Bank after death. Twelve had played professionally, seven in college, and two in high school.

After autopsy, 18 of the 21 had CTE — 16 of them at a high stage (McKee stage 3 or 4), and two at a low stage (McKee stage 1 or 2). Three had no CTE at all. Eleven of the twelve former professionals had high-stage CTE.

Then the researchers went back to the blood samples and measured a protein fragment called eMTBR-tau — short for endogenously cleaved microtubule-binding region tau. It’s a marker of the tau tangles that also form in Alzheimer’s disease. The result was striking. Blood levels of eMTBR-tau were significantly higher in the players with high-stage CTE than in those with low-stage CTE or no CTE at all. In fact, the marker did not rise in low-stage or no-CTE cases — only in the severe ones.

A Second Marker Could Separate CTE From Alzheimer’s

Even better, the researchers checked a second marker, p-tau217, which is known to track Alzheimer’s disease specifically. It rose only in the players who also had Alzheimer’s. Five of the CTE cases had both diseases, and their eMTBR-tau levels were the highest of all. That suggests a two-marker blood test could one day tell CTE and Alzheimer’s apart, which matters enormously because their symptoms overlap so much.

“This is a game changer,” said Dr. Michael Alosco, the study’s corresponding author and co-director of clinical research at the BU CTE Center. “We are still in the discovery phase and it’s a small sample size, but if future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment.”

Scientist holding CTE blood test sample in laboratory with brain scans

Why Two Studies in One Week Matters So Much

A single small study can mislead. What makes this moment different is that a second, independent research team — led by Washington University School of Medicine in St. Louis — published in the same issue of JAMA and found the same thing using a different method on different patients.

The WashU team tested a closely related version of the marker, eMTBR-tau243. They used blood samples from more than 80 people with autopsy-confirmed brain diseases, plus healthy volunteers. Again, levels were elevated in people with autopsy-confirmed CTE. The story of how they found it is almost accidental: one patient with no Alzheimer’s at autopsy had an unexpectedly high level, and digging into that case led them to CTE.

“Many pharmaceutical companies are developing therapies that could potentially treat CTE, but we do not have biomarkers to identify the disease and to rapidly see if a treatment is working,” said Dr. Kanta Horie, co-senior author of the WashU study. “We are potentially opening a new door for diagnosing and treating CTE in living patients.”

Two teams, two methods, same signal. That’s the kind of replication scientists dream about — and it’s why researchers are calling this a milestone rather than just another promising result.

Myth vs. Fact: What This Test Can and Can’t Do Yet

The headlines are exciting, and that’s exactly why it’s worth slowing down for a minute. Here’s the honest picture:

Myth: You can get tested for CTE now. Fact: You can’t. The researchers are explicit: the blood test is not FDA-approved, it is not available to the public, and it should not be used to make diagnostic decisions about CTE until validation studies are finished.

Myth: The test catches CTE early. Fact: Not yet. In this study, the marker rose only in high-stage CTE. Low-stage cases looked the same as people with no CTE at all. Catching the disease early — when treatment would matter most — is still an unsolved problem.

Myth: Twenty-one players prove it works. Fact: Twenty-one players is a tiny sample. The researchers say so themselves, and there were no age-matched controls. The study also had very few low-stage cases to learn from. Larger validation studies are the next step, and the BU team is still enrolling participants in its DIAGNOSE CTE Research Project.

Myth: A positive result would mean your symptoms are definitely CTE. Fact: Symptoms like memory problems and mood changes have many causes, and Alzheimer’s also raises the marker. That’s why the two-marker approach — eMTBR-tau plus p-tau217 — is so important, and why it still needs proving.

None of this makes the finding less important. It just means the timeline is measured in years of validation work, not weeks.

What Athletes Can Do Right Now

A blood test is coming — maybe. In the meantime, the best protection for your brain is still the unglamorous stuff that works today:

Report every hit that feels wrong. Not just the ones that knock you down. Tell your coach, your athletic trainer, or your doctor about dizziness, fogginess, headaches, or “just feeling off” after contact. The hits you hide are the ones nobody can help you with.

Respect the return-to-play process. Sitting out a week feels endless when your team needs you. But a second impact before the first one heals is one of the clearest risk factors for lasting damage. The protocol exists for a reason — follow it, even when you feel fine.

Look after the basics that protect your brain. Sleep, regular exercise, blood pressure control, and avoiding alcohol excess all support brain health. They’re the same habits that keep you performing. If you’re worried about your memory or mood, see a clinician who specializes in neurodegenerative conditions rather than trying to self-diagnose from headlines.

Know your options if you’re a former player. Research programs like BU’s DIAGNOSE CTE project are actively enrolling former college and professional football players over 50. Participating in research is one of the most direct ways to push this science forward — and to get a thorough neurological workup in the process.

Football helmet on bench on the sideline — CTE blood test and athlete brain health

FAQs

Can I get a blood test for CTE today?

No. The test is still in the research phase. It is not FDA-approved, not commercially available, and the researchers warn it should not be used for diagnosis until larger validation studies are complete. If someone offers you a “CTE blood test” online, that’s a red flag, not a breakthrough.

Who is most at risk of CTE?

The strongest evidence is in people with years of repetitive head impacts. That includes American football players, boxers, rugby players, ice hockey players, soccer players who head the ball frequently, and military veterans exposed to blast injuries. Risk rises with the number of years played and the level of contact — in the BU study, 11 of 12 former professionals had high-stage CTE at autopsy.

If the test works, what changes for athletes?

Everything downstream. A reliable blood test would let doctors diagnose CTE in living patients, enrol the right people in clinical trials, and measure whether a treatment is actually working — none of which is possible today. It would also give athletes and families real information for decisions about continuing to play, instead of the uncertainty they live with now.

The Bottom Line

For the first time, scientists can look at a vial of blood and see a signal that tracks with severe CTE. Two independent teams found it in the same week. The study is small, the test isn’t available, and early-stage disease still hides from it. But the door that has been locked since CTE was first described is finally starting to open. For every athlete who has ever taken a hit and wondered what it might cost them years later, that’s a genuinely big deal.

This article is for informational purposes only and is not medical advice. If you are concerned about head injuries, memory, or mood changes, please speak to a qualified healthcare professional.